vs
Apellis Pharmaceuticals, Inc.（APLS）与FIRST INTERSTATE BANCSYSTEM INC（FIBK）财务数据对比。点击上方公司名可切换其他公司
FIRST INTERSTATE BANCSYSTEM INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$313.0M vs $199.9M），FIRST INTERSTATE BANCSYSTEM INC净利率更高（34.8% vs -29.5%，领先64.2%），FIRST INTERSTATE BANCSYSTEM INC同比增速更快（19.8% vs -5.9%），过去两年FIRST INTERSTATE BANCSYSTEM INC的营收复合增速更高（13.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
第一州际银行系统公司是总部位于美国蒙大拿州比灵斯的金融控股公司，旗下拥有第一州际银行，该社区银行的服务网点覆盖美国西部和中西部共14个州，按总资产计算是蒙大拿州规模最大的银行。
APLS vs FIBK — 直观对比
营收规模更大
FIBK
是对方的1.6倍
$199.9M
营收增速更快
FIBK
高出25.7%
-5.9%
净利率更高
FIBK
高出64.2%
-29.5%
两年增速更快
FIBK
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $313.0M |
| 净利润 | $-59.0M | $108.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 44.5% |
| 净利率 | -29.5% | 34.8% |
| 营收同比 | -5.9% | 19.8% |
| 净利润同比 | -62.2% | 108.8% |
| 每股收益（稀释后） | $-0.40 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFIBK
| Q4 25 | $199.9M | $313.0M | ||
| Q3 25 | $458.6M | $250.5M | ||
| Q2 25 | $178.5M | $248.3M | ||
| Q1 25 | $166.8M | $247.0M | ||
| Q4 24 | $212.5M | $261.3M | ||
| Q3 24 | $196.8M | $251.9M | ||
| Q2 24 | $199.7M | $244.3M | ||
| Q1 24 | $172.3M | $242.2M |
净利润APLSFIBK
| Q4 25 | $-59.0M | $108.8M | ||
| Q3 25 | $215.7M | $71.4M | ||
| Q2 25 | $-42.2M | $71.7M | ||
| Q1 25 | $-92.2M | $50.2M | ||
| Q4 24 | $-36.4M | $52.1M | ||
| Q3 24 | $-57.4M | $55.5M | ||
| Q2 24 | $-37.7M | $60.0M | ||
| Q1 24 | $-66.4M | $58.4M |
营业利润率APLSFIBK
| Q4 25 | -25.6% | 44.5% | ||
| Q3 25 | 48.7% | 37.0% | ||
| Q2 25 | -18.6% | 37.7% | ||
| Q1 25 | -50.0% | 26.9% | ||
| Q4 24 | -12.3% | 25.5% | ||
| Q3 24 | -24.0% | 28.9% | ||
| Q2 24 | -14.7% | 32.1% | ||
| Q1 24 | -36.0% | 31.7% |
净利率APLSFIBK
| Q4 25 | -29.5% | 34.8% | ||
| Q3 25 | 47.0% | 28.5% | ||
| Q2 25 | -23.6% | 28.9% | ||
| Q1 25 | -55.3% | 20.3% | ||
| Q4 24 | -17.1% | 19.9% | ||
| Q3 24 | -29.2% | 22.0% | ||
| Q2 24 | -18.9% | 24.6% | ||
| Q1 24 | -38.5% | 24.1% |
每股收益（稀释后）APLSFIBK
| Q4 25 | $-0.40 | $1.07 | ||
| Q3 25 | $1.67 | $0.69 | ||
| Q2 25 | $-0.33 | $0.69 | ||
| Q1 25 | $-0.74 | $0.49 | ||
| Q4 24 | $-0.30 | $0.50 | ||
| Q3 24 | $-0.46 | $0.54 | ||
| Q2 24 | $-0.30 | $0.58 | ||
| Q1 24 | $-0.54 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $146.3M |
| 股东权益账面价值 | $370.1M | $3.4B |
| 总资产 | $1.1B | $26.6B |
| 负债/权益比越低杠杆越低 | — | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资APLSFIBK
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSFIBK
| Q4 25 | — | $146.3M | ||
| Q3 25 | — | $146.2M | ||
| Q2 25 | — | $252.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $132.2M | ||
| Q3 24 | — | $137.3M | ||
| Q2 24 | — | $383.4M | ||
| Q1 24 | $93.1M | $370.8M |
股东权益APLSFIBK
| Q4 25 | $370.1M | $3.4B | ||
| Q3 25 | $401.2M | $3.4B | ||
| Q2 25 | $156.3M | $3.4B | ||
| Q1 25 | $164.2M | $3.4B | ||
| Q4 24 | $228.5M | $3.3B | ||
| Q3 24 | $237.1M | $3.4B | ||
| Q2 24 | $264.3M | $3.2B | ||
| Q1 24 | $266.7M | $3.2B |
总资产APLSFIBK
| Q4 25 | $1.1B | $26.6B | ||
| Q3 25 | $1.1B | $27.3B | ||
| Q2 25 | $821.4M | $27.6B | ||
| Q1 25 | $807.3M | $28.3B | ||
| Q4 24 | $885.1M | $29.1B | ||
| Q3 24 | $901.9M | $29.6B | ||
| Q2 24 | $904.5M | $30.3B | ||
| Q1 24 | $831.9M | $30.1B |
负债/权益比APLSFIBK
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | 0.35× | 0.12× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $305.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 2.81× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSFIBK
| Q4 25 | $-14.2M | $305.6M | ||
| Q3 25 | $108.5M | $91.7M | ||
| Q2 25 | $4.4M | $68.1M | ||
| Q1 25 | $-53.4M | $78.5M | ||
| Q4 24 | $19.4M | $355.0M | ||
| Q3 24 | $34.1M | $89.9M | ||
| Q2 24 | $-8.3M | $82.3M | ||
| Q1 24 | $-133.0M | $87.6M |
自由现金流APLSFIBK
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSFIBK
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSFIBK
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSFIBK
| Q4 25 | — | 2.81× | ||
| Q3 25 | 0.50× | 1.28× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 6.81× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FIBK
暂无分部数据
